Rexahn’s Human Data Confirms AntiCancer Advantage

New results shown at last week’s European Cancer Congress (NYSE:ECC) supported evidence that RX3117 and Supinoxin, developed by Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), work well in humans – a big step up from preclinical data in mice. Phase Ib studies conducted the past year where safety and tolerance were observed mirrored animal trials, but the best news is efficacy in people, confirming Rexahn’s theory that its drugs’ mechanisms of action pinpoint crucial biological pathways in cancer progression….

- Seeking Alpha -

Click here for more information